Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Trial Profile

Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RICOVER-60
  • Most Recent Events

    • 01 Aug 2017 Results of pooled data of clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within two prospective clinical trials (RICOVER-60 and R-MegaCHOEP) of the German high-grade non-Hodgkin's lymphoma study group were, published in the Journal of Clinical Oncology.
    • 06 Jun 2017 Results of pooled data of anti-infective prophylaxis with aciclovir and cotrimoxazole from two prospective DSHNHL trials (OPTIMAL > 60 and RICOVER-60) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Dec 2016 Results of retrospective analysis from this and other study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top